News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
July, 2025
July 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
ESGO – Juan Carlos Torrejon Becerra completed the ESGO training program
ESGO/LinkedIn
Apr 22, 2025, 06:26

ESGO – Juan Carlos Torrejon Becerra completed the ESGO training program

European Society of Gynaecological Oncology (ESGO) posted on LinkedIn:

“We would like to congratulate Dr. Juan Carlos Torrejon Becerra from University Hospital of Bellvitge (ICS), Barcelona, Spain for completing the ESGO training program and becoming ​a European Gynaecological Oncologist.”

cancer ESGO Juan Carlos Torrejon Becerra OncoDaily Oncology University Hospital of Bellvitge
Special Coverage
Blog
Jul 27, 2025, 17:40
Aladina Foundation's Psychooncologists Offer a Consultation Outside the Hospital for Free
Opinion
Jul 27, 2025, 17:27
Ian Davis: Why Chemotherapy Has Not Stopped Working in Metastatic Prostate Cancer for More than 20 Years
Blog
Jul 27, 2025, 16:53
Luis E. Raez: The FLASCO “Breaking Barriers” Conference Returns This November
Career
Jul 27, 2025, 16:20
Justin Perry Has Been Promoted to Associate Member at Memorial Sloan Kettering Cancer Center
Blog
Jul 27, 2025, 16:04
Helena Linardou: ESMO Virtual Journal Club – July 2025 Edition
Blog
Jul 27, 2025, 15:57
A Deep Dive Into the Most Important Lung Cancer Trials Presented at ASCO25 - IASLC
Blog
Jul 27, 2025, 15:38
Sergio Cifuentes Canaval: First Meeting of Young Oncologists Group
Science
Jul 27, 2025, 15:14
Talha Badar: PII Trial of CPX-351 and Venetoclax
Insight
Jul 27, 2025, 15:13
Potential Breakthrough for Glioma: Servier’s Therapy Nears EMA Approval - Servier Pharmaceuticals
Blog
Jul 27, 2025, 15:03
Neil Gross: Giving an Update on the Progress of HN014 C-PRE for Skin CSCC Cancer
Blog
Jul 27, 2025, 14:26
Chadi Nabhan: How to Survive and Thrive in Fellowship?
Blog
Jul 27, 2025, 14:15
Alireza Mansouri: What Does the Clinical Community vs General Public Think of GBM Clinical Trials?